IGF2BP2 在癌症治疗耐药中的新兴作用：从分子机制到未来潜力。

The Emerging Role of IGF2BP2 in Cancer Therapy Resistance: From Molecular Mechanism to Future Potential.

机构信息

Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200433, China.

出版信息

Int J Mol Sci. 2024 Nov 12;25(22):12150. doi: 10.3390/ijms252212150.

DOI:10.3390/ijms252212150

PMID:39596216

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11595103/

Abstract

Tumor resistance is one of the primary reasons for cancer treatment failure, significantly limiting the options and efficacy of cancer therapies. Therefore, overcoming resistance has become a critical factor in improving cancer treatment outcomes. IGF2BP2, as a reader of m6A methylation, plays a pivotal role in the post-transcriptional regulation of RNA through the methylation of m6A sites. It not only contributes to cancer initiation and progression but also plays a key role in tumor drug resistance. This review provides a comprehensive summary of the mechanisms by which IGF2BP2 contributes to therapy resistance, with the aim of improving the efficacy of chemotherapy in cancer treatment. Advancing research in this area is crucial for developing more effective therapies that could significantly improve the quality of life for cancer patients.

摘要

肿瘤耐药性是癌症治疗失败的主要原因之一，极大地限制了癌症治疗的选择和效果。因此，克服耐药性已成为改善癌症治疗效果的关键因素。IGF2BP2 作为 m6A 甲基化的阅读器，通过 m6A 位点的甲基化，在 RNA 的转录后调控中发挥关键作用。它不仅促进癌症的发生和发展，而且在肿瘤耐药性中也起着关键作用。本综述全面总结了 IGF2BP2 促进治疗耐药性的机制，旨在提高化疗在癌症治疗中的疗效。推进该领域的研究对于开发更有效的治疗方法至关重要，这可能会显著提高癌症患者的生活质量。